E-LIB Suche - Ergebnisse für: Colangeli, V

1

Plasma trough concentrations of darunavir/ritonavir and ral..:

Calza, L ; Colangeli, V ; Magistrelli, E...
HIV Medicine. 18 (2017) 7 - p. 474-481 , 2017

Link: https://doi.org/10.1111/..

2

Subtypes of depressive symptoms and inflammatory biomarkers..:

Norcini Pala, A. ; Steca, P. ; Bagrodia, R....
Brain, Behavior, and Immunity. 56 (2016) - p. 105-113 , 2016

Link: https://doi.org/10.1016/..

3

No correlation between statin exposure and incident diabete..:

Calza, L ; Colangeli, V ; Magistrelli, E...
HIV Medicine. 17 (2016) 8 - p. 631-633 , 2016

Link: https://doi.org/10.1111/..

4

Evaluation of glomerular filtration rate in HIV-1-infected ..:

Tordato, F ; Cozzi Lepri, A ; Cicconi, P...
HIV Medicine. 12 (2010) 1 - p. 4-13 , 2010

Link: https://doi.org/10.1111/..

5

Disseminated histoplasmosis with atypical cutaneous lesions..:

Calza, L ; Manfredi, R ; Donzelli, C...
HIV Medicine. 4 (2003) 2 - p. 145-148 , 2003

Link: https://doi.org/10.1046/..

6

Merkel cell carcinoma in a human immunodeficiency virus-inf..:

Calza, L. ; Beltrami, C. ; Manfredi, R....
British Journal of Dermatology. 146 (2002) 5 - p. 895-898 , 2002

Link: https://doi.org/10.1046/..

7

Antibodies against full-length Tat protein and some low-mol..:

Re, M.C. ; Vignoli, M. ; Furlini, G....
Journal of Clinical Virology. 21 (2001) 1 - p. 81-89 , 2001

Link: https://doi.org/10.1016/..

8

Serum IgG Antibodies to Human Herpesvirus-6 (HHV-6) Do Not ..:

Dorrucci, M. ; Rezza, G. ; Andreoni, M....
European Journal of Epidemiology. 15 (1999) 4 - p. 317-322 , 1999

Link: https://www.jstor.org/st..

9

Human Herpesvirus 8 Seropositivity and Risk of Kaposi's Sar..:

Rezza, G. ; Andreoni, M. ; Dorrucci, M....
JNCI Journal of the National Cancer Institute. 91 (1999) 17 - p. 1468-1474 , 1999

Link: https://doi.org/10.1093/..

10

COVID-19 in patients with HIV-1 infection: a single-centre ..:

Calza L ; Bon I ; Tadolini M...
info:eu-repo/semantics/altIdentifier/pmid/32748333. , 2021

Link: https://hdl.handle.net/1..

11

The effect of switching to Maraviroc + Darunavir/ritonavir ..:

Rossetti, B ; Gagliardini, R ; Sterrantino, G...
info:eu-repo/semantics/altIdentifier/pmid/30789452. , 2019

Link: http://hdl.handle.net/24..

12

The effect of switching to Maraviroc + Darunavir/Ritonavir ..:

Rossetti B ; Gagliardini R ; Sterrantino G...
info:eu-repo/semantics/altIdentifier/pmid/30789452. , 2019

Link: http://hdl.handle.net/11..

13

Biochemical and inflammatory modifications after switching ..:

Quiros-Roldan E ; Magro P ; Raffetti E...
info:eu-repo/semantics/altIdentifier/pmid/29940869. , 2018

Link: http://hdl.handle.net/11..

14

Biochemical and inflammatory modifications after switching ..:

Quiros-Roldan, E ; Magro, Paola ; Raffetti, Elena...
info:eu-repo/semantics/altIdentifier/pmid/29940869. , 2018

Link: http://hdl.handle.net/24..

15

Switch to maraviroc with darunavir/r, both QD, in patients ..:

Rossetti, B ; Gagliardini, R ; Meini, G...
https://discovery.ucl.ac.uk/id/eprint/10040498/1/journal.pone.0187393.pdf. , 2017

Link: https://discovery.ucl.ac..